MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
ACL InjuryMeniscus TearPost-traumatic Osteoarthritis
Interventions
DRUG

Montelukast

The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.

DRUG

Placebo

An oral placebo will be taken daily for 6 months post surgery.

Trial Locations (1)

40504

RECRUITING

UK Healthcare at Turfland, Lexington

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Duke University

OTHER

collaborator

The Cleveland Clinic

OTHER

collaborator

University of California, San Francisco

OTHER

lead

Austin V Stone

OTHER